Where Will Hershey Stock Be In 1 Year?
Chocolate stocks used to be the epitome of sleepy stability,…
Sell
46
LEGN Quote, Financials, Valuation and Earnings
Last price:
$35.51
Seasonality move
:
-9.03%
Day range:
$35.81 - $36.77
52-week range:
$27.34 - $60.87
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.04x
P/B ratio:
6.49x
Volume:
1.1M
Avg. volume:
2M
1-year change:
-19.74%
Market cap:
$6.6B
Revenue:
$627.2M
EPS (TTM):
-$1.20
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LEGN
Legend Biotech
|
$233.1M | -$0.21 | 25.53% | -120.66% | $75.69 |
|
ALNY
Alnylam Pharmaceuticals
|
$633.5M | -$0.05 | -3.52% | -58.59% | $325.06 |
|
ARDX
Ardelyx
|
$82.2M | -$0.14 | 12.93% | -95.54% | $10.73 |
|
GILD
Gilead Sciences
|
$7B | $1.95 | -0.13% | 51.38% | $116.77 |
|
RCEL
AVITA Medical
|
$22.4M | -$0.23 | 47.51% | -61.01% | $16.95 |
|
TGTX
TG Therapeutics
|
$147.8M | $0.30 | 101.13% | 653.48% | $41.20 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LEGN
Legend Biotech
|
$35.91 | $75.69 | $6.6B | -- | $0.00 | 0% | 9.04x |
|
ALNY
Alnylam Pharmaceuticals
|
$329.77 | $325.06 | $43B | -- | $0.00 | 0% | 18.05x |
|
ARDX
Ardelyx
|
$4.19 | $10.73 | $1B | -- | $0.00 | 0% | 2.74x |
|
GILD
Gilead Sciences
|
$111.51 | $116.77 | $138.7B | 23.48x | $0.79 | 2.8% | 4.89x |
|
RCEL
AVITA Medical
|
$5.16 | $16.95 | $136.4M | -- | $0.00 | 0% | 1.87x |
|
TGTX
TG Therapeutics
|
$36.29 | $41.20 | $5.8B | 151.21x | $0.00 | 0% | 15.10x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LEGN
Legend Biotech
|
23.1% | 0.839 | 4.9% | 5.00x |
|
ALNY
Alnylam Pharmaceuticals
|
89.88% | 0.837 | 2.91% | 2.84x |
|
ARDX
Ardelyx
|
50.95% | -0.143 | 12.88% | 3.43x |
|
GILD
Gilead Sciences
|
56.56% | 0.135 | 17.9% | 1.00x |
|
RCEL
AVITA Medical
|
112.39% | -0.697 | 19.27% | 1.65x |
|
TGTX
TG Therapeutics
|
-- | -0.654 | -- | 2.01x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LEGN
Legend Biotech
|
$123.7M | -$50.6M | -15.63% | -19.84% | -48.23% | -$105.8M |
|
ALNY
Alnylam Pharmaceuticals
|
$523.1M | $18.1M | -26.39% | -- | -0.5% | -$127.3M |
|
ARDX
Ardelyx
|
$61.8M | -$36.3M | -19.51% | -34.68% | -45.91% | -$38.8M |
|
GILD
Gilead Sciences
|
$5.1B | $2.5B | 13.82% | 32.29% | 28.63% | $1.7B |
|
RCEL
AVITA Medical
|
$15.7M | -$11.8M | -102.9% | -415.55% | -68.15% | -$10.5M |
|
TGTX
TG Therapeutics
|
$105.3M | $8.6M | 11.64% | 19.78% | 10.12% | -$28.7M |
Legend Biotech vs. Competitors
-
Which has Higher Returns LEGN or ALNY?
Alnylam Pharmaceuticals has a net margin of -51.74% compared to Legend Biotech's net margin of -9.67%. Legend Biotech's return on equity of -19.84% beat Alnylam Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech63.42% -$0.54 $1.3B ALNYAlnylam Pharmaceuticals88.04% -$0.44 $1.1B -
What do Analysts Say About LEGN or ALNY?
Legend Biotech has a consensus price target of $75.69, signalling upside risk potential of 110.78%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $325.06 which suggests that it could fall by -1.43%. Given that Legend Biotech has higher upside potential than Alnylam Pharmaceuticals, analysts believe Legend Biotech is more attractive than Alnylam Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech11 1 0 ALNYAlnylam Pharmaceuticals13 7 1 -
Is LEGN or ALNY More Risky?
Legend Biotech has a beta of 0.192, which suggesting that the stock is 80.792% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.226, suggesting its less volatile than the S&P 500 by 77.386%.
-
Which is a Better Dividend Stock LEGN or ALNY?
Legend Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or ALNY?
Legend Biotech quarterly revenues are $195.1M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. Legend Biotech's net income of -$100.9M is lower than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, Legend Biotech's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech is 9.04x versus 18.05x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech9.04x -- $195.1M -$100.9M ALNYAlnylam Pharmaceuticals18.05x -- $594.2M -$57.5M
-
Which has Higher Returns LEGN or ARDX?
Ardelyx has a net margin of -51.74% compared to Legend Biotech's net margin of -55.52%. Legend Biotech's return on equity of -19.84% beat Ardelyx's return on equity of -34.68%.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech63.42% -$0.54 $1.3B ARDXArdelyx83.4% -$0.17 $297M -
What do Analysts Say About LEGN or ARDX?
Legend Biotech has a consensus price target of $75.69, signalling upside risk potential of 110.78%. On the other hand Ardelyx has an analysts' consensus of $10.73 which suggests that it could grow by 156.02%. Given that Ardelyx has higher upside potential than Legend Biotech, analysts believe Ardelyx is more attractive than Legend Biotech.
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech11 1 0 ARDXArdelyx8 1 0 -
Is LEGN or ARDX More Risky?
Legend Biotech has a beta of 0.192, which suggesting that the stock is 80.792% less volatile than S&P 500. In comparison Ardelyx has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.538%.
-
Which is a Better Dividend Stock LEGN or ARDX?
Legend Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or ARDX?
Legend Biotech quarterly revenues are $195.1M, which are larger than Ardelyx quarterly revenues of $74.1M. Legend Biotech's net income of -$100.9M is lower than Ardelyx's net income of -$41.1M. Notably, Legend Biotech's price-to-earnings ratio is -- while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech is 9.04x versus 2.74x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech9.04x -- $195.1M -$100.9M ARDXArdelyx2.74x -- $74.1M -$41.1M
-
Which has Higher Returns LEGN or GILD?
Gilead Sciences has a net margin of -51.74% compared to Legend Biotech's net margin of 19.72%. Legend Biotech's return on equity of -19.84% beat Gilead Sciences's return on equity of 32.29%.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech63.42% -$0.54 $1.3B GILDGilead Sciences76.9% $1.04 $44B -
What do Analysts Say About LEGN or GILD?
Legend Biotech has a consensus price target of $75.69, signalling upside risk potential of 110.78%. On the other hand Gilead Sciences has an analysts' consensus of $116.77 which suggests that it could grow by 4.72%. Given that Legend Biotech has higher upside potential than Gilead Sciences, analysts believe Legend Biotech is more attractive than Gilead Sciences.
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech11 1 0 GILDGilead Sciences15 11 0 -
Is LEGN or GILD More Risky?
Legend Biotech has a beta of 0.192, which suggesting that the stock is 80.792% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.014%.
-
Which is a Better Dividend Stock LEGN or GILD?
Legend Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.8% to investors and pays a quarterly dividend of $0.79 per share. Legend Biotech pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or GILD?
Legend Biotech quarterly revenues are $195.1M, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Legend Biotech's net income of -$100.9M is lower than Gilead Sciences's net income of $1.3B. Notably, Legend Biotech's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 23.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech is 9.04x versus 4.89x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech9.04x -- $195.1M -$100.9M GILDGilead Sciences4.89x 23.48x $6.7B $1.3B
-
Which has Higher Returns LEGN or RCEL?
AVITA Medical has a net margin of -51.74% compared to Legend Biotech's net margin of -74.86%. Legend Biotech's return on equity of -19.84% beat AVITA Medical's return on equity of -415.55%.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech63.42% -$0.54 $1.3B RCELAVITA Medical84.7% -$0.53 $36.9M -
What do Analysts Say About LEGN or RCEL?
Legend Biotech has a consensus price target of $75.69, signalling upside risk potential of 110.78%. On the other hand AVITA Medical has an analysts' consensus of $16.95 which suggests that it could grow by 227.57%. Given that AVITA Medical has higher upside potential than Legend Biotech, analysts believe AVITA Medical is more attractive than Legend Biotech.
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech11 1 0 RCELAVITA Medical3 1 0 -
Is LEGN or RCEL More Risky?
Legend Biotech has a beta of 0.192, which suggesting that the stock is 80.792% less volatile than S&P 500. In comparison AVITA Medical has a beta of 1.518, suggesting its more volatile than the S&P 500 by 51.797%.
-
Which is a Better Dividend Stock LEGN or RCEL?
Legend Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech pays -- of its earnings as a dividend. AVITA Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or RCEL?
Legend Biotech quarterly revenues are $195.1M, which are larger than AVITA Medical quarterly revenues of $18.5M. Legend Biotech's net income of -$100.9M is lower than AVITA Medical's net income of -$13.9M. Notably, Legend Biotech's price-to-earnings ratio is -- while AVITA Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech is 9.04x versus 1.87x for AVITA Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech9.04x -- $195.1M -$100.9M RCELAVITA Medical1.87x -- $18.5M -$13.9M
-
Which has Higher Returns LEGN or TGTX?
TG Therapeutics has a net margin of -51.74% compared to Legend Biotech's net margin of 4.19%. Legend Biotech's return on equity of -19.84% beat TG Therapeutics's return on equity of 19.78%.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech63.42% -$0.54 $1.3B TGTXTG Therapeutics87.14% $0.03 $237.3M -
What do Analysts Say About LEGN or TGTX?
Legend Biotech has a consensus price target of $75.69, signalling upside risk potential of 110.78%. On the other hand TG Therapeutics has an analysts' consensus of $41.20 which suggests that it could grow by 13.53%. Given that Legend Biotech has higher upside potential than TG Therapeutics, analysts believe Legend Biotech is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech11 1 0 TGTXTG Therapeutics5 0 0 -
Is LEGN or TGTX More Risky?
Legend Biotech has a beta of 0.192, which suggesting that the stock is 80.792% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.
-
Which is a Better Dividend Stock LEGN or TGTX?
Legend Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or TGTX?
Legend Biotech quarterly revenues are $195.1M, which are larger than TG Therapeutics quarterly revenues of $120.9M. Legend Biotech's net income of -$100.9M is lower than TG Therapeutics's net income of $5.1M. Notably, Legend Biotech's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 151.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech is 9.04x versus 15.10x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech9.04x -- $195.1M -$100.9M TGTXTG Therapeutics15.10x 151.21x $120.9M $5.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will KNOT Stock Be In 1 Year?
In the case of KNOT Offshore Partners (KNOP), most headlines…
Why Is Goldman Sachs Stock Up So Much?
Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…
Stock Ideas
Buy
63
Is NVDA Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 53x
Buy
60
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
92
BGL alert for Jul 3
Blue Gold [BGL] is down 20.3% over the past day.
Sell
18
CNC alert for Jul 3
Centene [CNC] is down 1.3% over the past day.
Sell
12
MOH alert for Jul 3
Molina Healthcare [MOH] is up 0.3% over the past day.
